A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

August 16, 2024

Study Completion Date

August 16, 2024

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

BMS-986406

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

Carboplatin

Specified dose on specified days

DRUG

Pemetrexed

Specified dose on specified days

DRUG

Paclitaxel

Specified dose on specified days

Trial Locations (29)

1090

Local Institution - 0018, Jette

1200

Local Institution - 0012, Brussels

2000

Local Institution - 0023, Rosario

2650

Local Institution - 0015, Edegem

3080

Local Institution - 0024, Seoul

3722

Local Institution - 0027, Seoul

5002

Local Institution - 0032, Córdoba

6351

Local Institution - 0025, Seoul

8500

Local Institution - 0029, Viedma

13620

Local Institution - 0026, Seongnam-si

23298

Local Institution - 0006, Richmond

28027

Local Institution - 0014, Madrid

28041

Local Institution - 0009, Madrid

28050

Local Institution - 0016, Madrid

28078

Carolina BioOncology Institute, PLLC, Huntersville

29010

Local Institution - 0008, Málaga

31008

Local Institution - 0033, Pamplona

35213

Local Institution - 0021, Birmingham

57104

Sanford Cancer Center, Sioux Falls

75230

Mary Crowley Cancer Research - Medical City Hospital, Dallas

90025

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles

90404

UCLA Health, Los Angeles

92093

University California San Diego Moores Cancer Center, La Jolla

2778577

Local Institution - 0031, Kashiwa-shi

07601

Local Institution - 0001, Hackensack

C1280

Local Institution - 0028, Buenos Aires

08023

Local Institution - 0030, Barcelona

08035

Local Institution - 0017, Barcelona

08908

Institut Catala dOncologia ICO - Hospital Duran i Reynals Location, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05298592 - A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Biotech Hunter | Biotech Hunter